China Biopharma plant leak infects thousands with bacterial disease

▴ china-biopharma-plant-leak-infects-thousands-bacterial-disease
Chinese authorities found a biopharmaceutical plant had used expired disinfectant in its production of Brucella vaccines for animals between July and August

Thousands of people in northwest China have tested positive for a bacterial disease after a leak from a state-owned biopharmaceutical plant making animal vaccines last year.

Health officials in Lanzhou city said 3,245 people had contracted brucellosis, a disease often caused by close contact with infected animals or animal products that can bring about fevers, joint pain, and headaches.

Another 1,401 people tested as an early positive for the disease, and health authorities said there was no evidence of person-to-person transmission so far.

Chinese authorities found a biopharmaceutical plant had used expired disinfectant in its production of Brucella vaccines for animals between July and August last year -- meaning the bacteria was not eradicated in its factory exhaust.

Contaminated gas from the China Animal Husbandry Lanzhou Biopharmaceutical Factory in Lanzhou formed aerosols containing the bacteria, and this was then carried by wind to the Lanzhou Veterinary Research Institute, infecting nearly 200 people there as of December last year.

More than 20 students and faculty members of Lanzhou University, some of whom had been to the institute, subsequently tested positive as well, according to Xinhua news agency.

Lanzhou's health commission said Friday that sheep, cattle, and pigs were most commonly involved in the spread of the bacteria.

According to the US Centers for Disease Control and Prevention, person-to-person transmission of brucellosis is "extremely rare" but some symptoms may reoccur or never go away.

These include recurrent fevers, chronic fatigue, swelling of the heart, or arthritis.

The factory -- which apologized earlier this year -- has had its brucellosis vaccine production license revoked, Lanzhou authorities said.

Compensation for patients would start in batches from October, according to local authorities.

Tags : #China #Biopharma #Bacteria #Disease #Infects #Leak

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Harnessing AI for Early Alzheimer's Disease Diagnosis: IIT Indore's BreakthroughMay 06, 2024
Aurobindo Pharma's Bhiwadi Facility Under FDA Scrutiny: Understanding the ObservationsMay 06, 2024
Exploring the Role of Mediator Protein Complex in Cell Division: Implications for Disease ManagementMay 06, 2024
Akshay Tritiya Parna Mahotsav is to be held in the cityMay 04, 2024
Bharti Singh's Battle with Gallstones: Symptoms, Precautions, and Natural RemediesMay 04, 2024
Empowering Women's Health: New Mammogram GuidelinesMay 04, 2024
Rising Temperatures, Rising Risks: Addressing the Challenges of Heat StressMay 04, 2024
Gynoveda, India's First Ayurveda Fertility Company, Expands Reach with New Clinic in Pune, Set to Open 100 Clinics Across India by 2027May 03, 2024
Aptus Value Housing Finance India Limited, a leading Housing Finance Company has declared its financial results for the year ended March 31, 2024. FY 24 ResultsMay 03, 2024
TIPS FOR PREGNANCY CARE DURING SUMMERMay 03, 2024
The deadly intersection: TB and tobacco smoking co-epidemics in Indonesia Dr TARA SINGH BAM – CNSMay 03, 2024
Mintoak Expands Global Footprint with Strategic Leadership AppointmentsMay 03, 2024
The Future of Healthcare: 10 ways Telehealth is Improving Patient Outcomes and Reducing CostsMay 03, 2024
Understanding the Effects of a Keto Diet on Your Body: A One-Month JourneyMay 03, 2024
High Blood Pressure in Youth: A Precursor to Severe Heart ConditionsMay 03, 2024
High Blood Pressure in Youth: A Precursor to Severe Heart ConditionsMay 03, 2024
Microplastics in Human Brains: Understanding the Emerging Health ConcernMay 03, 2024
Federal Bank Wraps Up FY 24 With 24% Rise in Profit, highest NII, Maintains Robust Asset QualityMay 02, 2024